The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.
Merck (NYSE:MRK) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback